Gamma-linolenic acid treatment of rheumatoid arthritis: A Randomized, placebo-controlled trial

Robert B. Zurier, Ronald G. Rossetti, Eric W. Jacobson, Deborah M. Demarco, Nancy Y. Liu, Joseph E. Temming, Bernadette M. White, Michael Laposata

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Objective. To assess the clinical efficacy and adverse effects of γ- linolenic acid (GLA), a plant seed oil-derived unsaturated fatty acid that suppresses inflammation and joint tissue injury in animal models, in the treatment of active rheumatoid arthritis (RA). Methods. Fifty-six patients with active RA were randomized to treatment groups in a 6-month, double- blind trial of GLA versus placebo. This was followed by a 6-month, single- blind trial during which all patients received GLA. Patients were treated with 2.8 gm/day of GLA as the free fatty acid or with sunflower seed oil (placebo) administered in identical capsules. Results. Treatment with GLA for 6 months resulted in statistically significant and clinically relevant reductions in the signs and symptoms of disease activity in patients with RA. Overall meaningful responses (at least 25% improvement in 4 measures) were also better in the GLA treatment group (14 of 22 patients versus 4 of 19 in the placebo group; P = 0.015). During the second 6 months, both groups exhibited improvement in disease activity. Thus, patients taking GLA during the entire study showed progressive improvement during the second 6 months. In this group, 16 of 21 patients showed meaningful improvement at 12 months compared with study entry. Conclusion. GLA at doses used in this study is a well-tolerated and effective treatment for active RA. GLA is available as a component of several plant seed oils and is usually taken in far lower doses than were used in this trial. It is not approved in the United States for the treatment of any condition, and should not be viewed as therapy for any disease. Further controlled studies of its use in RA are warranted.

Original languageEnglish (US)
Pages (from-to)1808-1817
Number of pages10
JournalArthritis and Rheumatism
Volume39
Issue number11
DOIs
StatePublished - Nov 1996
Externally publishedYes

Fingerprint

gamma-Linolenic Acid
Rheumatoid Arthritis
Randomized Controlled Trials
Placebos
Plant Oils
Therapeutics
Seeds
alpha-Linolenic Acid
Unsaturated Fatty Acids
Nonesterified Fatty Acids
Signs and Symptoms
Capsules
Animal Models
Joints
Inflammation
Wounds and Injuries

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Zurier, R. B., Rossetti, R. G., Jacobson, E. W., Demarco, D. M., Liu, N. Y., Temming, J. E., ... Laposata, M. (1996). Gamma-linolenic acid treatment of rheumatoid arthritis: A Randomized, placebo-controlled trial. Arthritis and Rheumatism, 39(11), 1808-1817. https://doi.org/10.1002/art.1780391106

Gamma-linolenic acid treatment of rheumatoid arthritis : A Randomized, placebo-controlled trial. / Zurier, Robert B.; Rossetti, Ronald G.; Jacobson, Eric W.; Demarco, Deborah M.; Liu, Nancy Y.; Temming, Joseph E.; White, Bernadette M.; Laposata, Michael.

In: Arthritis and Rheumatism, Vol. 39, No. 11, 11.1996, p. 1808-1817.

Research output: Contribution to journalArticle

Zurier, RB, Rossetti, RG, Jacobson, EW, Demarco, DM, Liu, NY, Temming, JE, White, BM & Laposata, M 1996, 'Gamma-linolenic acid treatment of rheumatoid arthritis: A Randomized, placebo-controlled trial', Arthritis and Rheumatism, vol. 39, no. 11, pp. 1808-1817. https://doi.org/10.1002/art.1780391106
Zurier RB, Rossetti RG, Jacobson EW, Demarco DM, Liu NY, Temming JE et al. Gamma-linolenic acid treatment of rheumatoid arthritis: A Randomized, placebo-controlled trial. Arthritis and Rheumatism. 1996 Nov;39(11):1808-1817. https://doi.org/10.1002/art.1780391106
Zurier, Robert B. ; Rossetti, Ronald G. ; Jacobson, Eric W. ; Demarco, Deborah M. ; Liu, Nancy Y. ; Temming, Joseph E. ; White, Bernadette M. ; Laposata, Michael. / Gamma-linolenic acid treatment of rheumatoid arthritis : A Randomized, placebo-controlled trial. In: Arthritis and Rheumatism. 1996 ; Vol. 39, No. 11. pp. 1808-1817.
@article{73bb7b200c1f4baf918a0ed670c80be5,
title = "Gamma-linolenic acid treatment of rheumatoid arthritis: A Randomized, placebo-controlled trial",
abstract = "Objective. To assess the clinical efficacy and adverse effects of γ- linolenic acid (GLA), a plant seed oil-derived unsaturated fatty acid that suppresses inflammation and joint tissue injury in animal models, in the treatment of active rheumatoid arthritis (RA). Methods. Fifty-six patients with active RA were randomized to treatment groups in a 6-month, double- blind trial of GLA versus placebo. This was followed by a 6-month, single- blind trial during which all patients received GLA. Patients were treated with 2.8 gm/day of GLA as the free fatty acid or with sunflower seed oil (placebo) administered in identical capsules. Results. Treatment with GLA for 6 months resulted in statistically significant and clinically relevant reductions in the signs and symptoms of disease activity in patients with RA. Overall meaningful responses (at least 25{\%} improvement in 4 measures) were also better in the GLA treatment group (14 of 22 patients versus 4 of 19 in the placebo group; P = 0.015). During the second 6 months, both groups exhibited improvement in disease activity. Thus, patients taking GLA during the entire study showed progressive improvement during the second 6 months. In this group, 16 of 21 patients showed meaningful improvement at 12 months compared with study entry. Conclusion. GLA at doses used in this study is a well-tolerated and effective treatment for active RA. GLA is available as a component of several plant seed oils and is usually taken in far lower doses than were used in this trial. It is not approved in the United States for the treatment of any condition, and should not be viewed as therapy for any disease. Further controlled studies of its use in RA are warranted.",
author = "Zurier, {Robert B.} and Rossetti, {Ronald G.} and Jacobson, {Eric W.} and Demarco, {Deborah M.} and Liu, {Nancy Y.} and Temming, {Joseph E.} and White, {Bernadette M.} and Michael Laposata",
year = "1996",
month = "11",
doi = "10.1002/art.1780391106",
language = "English (US)",
volume = "39",
pages = "1808--1817",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Gamma-linolenic acid treatment of rheumatoid arthritis

T2 - A Randomized, placebo-controlled trial

AU - Zurier, Robert B.

AU - Rossetti, Ronald G.

AU - Jacobson, Eric W.

AU - Demarco, Deborah M.

AU - Liu, Nancy Y.

AU - Temming, Joseph E.

AU - White, Bernadette M.

AU - Laposata, Michael

PY - 1996/11

Y1 - 1996/11

N2 - Objective. To assess the clinical efficacy and adverse effects of γ- linolenic acid (GLA), a plant seed oil-derived unsaturated fatty acid that suppresses inflammation and joint tissue injury in animal models, in the treatment of active rheumatoid arthritis (RA). Methods. Fifty-six patients with active RA were randomized to treatment groups in a 6-month, double- blind trial of GLA versus placebo. This was followed by a 6-month, single- blind trial during which all patients received GLA. Patients were treated with 2.8 gm/day of GLA as the free fatty acid or with sunflower seed oil (placebo) administered in identical capsules. Results. Treatment with GLA for 6 months resulted in statistically significant and clinically relevant reductions in the signs and symptoms of disease activity in patients with RA. Overall meaningful responses (at least 25% improvement in 4 measures) were also better in the GLA treatment group (14 of 22 patients versus 4 of 19 in the placebo group; P = 0.015). During the second 6 months, both groups exhibited improvement in disease activity. Thus, patients taking GLA during the entire study showed progressive improvement during the second 6 months. In this group, 16 of 21 patients showed meaningful improvement at 12 months compared with study entry. Conclusion. GLA at doses used in this study is a well-tolerated and effective treatment for active RA. GLA is available as a component of several plant seed oils and is usually taken in far lower doses than were used in this trial. It is not approved in the United States for the treatment of any condition, and should not be viewed as therapy for any disease. Further controlled studies of its use in RA are warranted.

AB - Objective. To assess the clinical efficacy and adverse effects of γ- linolenic acid (GLA), a plant seed oil-derived unsaturated fatty acid that suppresses inflammation and joint tissue injury in animal models, in the treatment of active rheumatoid arthritis (RA). Methods. Fifty-six patients with active RA were randomized to treatment groups in a 6-month, double- blind trial of GLA versus placebo. This was followed by a 6-month, single- blind trial during which all patients received GLA. Patients were treated with 2.8 gm/day of GLA as the free fatty acid or with sunflower seed oil (placebo) administered in identical capsules. Results. Treatment with GLA for 6 months resulted in statistically significant and clinically relevant reductions in the signs and symptoms of disease activity in patients with RA. Overall meaningful responses (at least 25% improvement in 4 measures) were also better in the GLA treatment group (14 of 22 patients versus 4 of 19 in the placebo group; P = 0.015). During the second 6 months, both groups exhibited improvement in disease activity. Thus, patients taking GLA during the entire study showed progressive improvement during the second 6 months. In this group, 16 of 21 patients showed meaningful improvement at 12 months compared with study entry. Conclusion. GLA at doses used in this study is a well-tolerated and effective treatment for active RA. GLA is available as a component of several plant seed oils and is usually taken in far lower doses than were used in this trial. It is not approved in the United States for the treatment of any condition, and should not be viewed as therapy for any disease. Further controlled studies of its use in RA are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0029861680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029861680&partnerID=8YFLogxK

U2 - 10.1002/art.1780391106

DO - 10.1002/art.1780391106

M3 - Article

C2 - 8912502

AN - SCOPUS:0029861680

VL - 39

SP - 1808

EP - 1817

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 11

ER -